IceCure Medical Gains IRB Approval For ChoICE Breast Cancer Cryoablation Study As West Cancer Center

IceCure Medical (ICCM) received IRB approval for its ChoICE study on ProSense cryoablation system for low-risk breast cancer. The study will evaluate the system in patients aged 70+ at West Cancer Center. ProSense is FDA-approved for this use. Earlier trial showed 3.1% local recurrence rate. ICCM stock closed at $2.52, up 0.40% in pre-market.

Original reporting
Published Aug 20, 2026, 1:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 1:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$ICCM
Bullish
high confidence
Mentioned
$ICCM
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$ICCMBullishMed
01

Why it matters

The study aims to generate real‑world evidence, supporting regulatory and payer acceptance.

02

Market read

First‑time IRB clearance provides a new catalyst for ICCM, potentially influencing its share price.

03

What to watch

Reimbursement policies and competition from surgical alternatives could constrain adoption.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

IceCure Medical announced IRB approval for a post‑marketing study of its ProSense system in patients 70+ with low‑risk breast cancer.

Company-level read

Ticker impact

$ICCMBullishHigh confidence
Context

IRB approval for the post‑marketing ChoICE Study of ProSense cryoablation in low‑risk breast cancer.

Expected impact

Modest upside as investors anticipate future sales growth.

Evidence & confidence

Clinical‑trial progress is a key catalyst for biotech stocks; IRB clearance is a fresh, material development.

Market effects

May boost confidence in minimally invasive breast‑cancer devices and related med‑tech sector.

Limited to U.S. biotech investors; no broader regional effect.

Low; relevance confined to niche oncology device market.

Counterpoint

Study results could be negative, limiting commercial upside despite approval.

Key entities

  • IceCure Medical Ltd.

    Developer of ProSense cryoablation system.

  • West Cancer Center & Research Institute

    IRB granting body for the ChoICE study.

Related articles

$ICCMMed

IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation

IceCure Medical (ICCM) announced the successful treatment of the first patient in its ChoICE post-marketing study for breast cancer cryoablation. The study, led by West Cancer Center in Tennessee, aims to enroll 400 patients across 30 U.S. sites. The company's ProSense® system is FDA-cleared for specific breast cancer treatments. IceCure expects the study to support broader adoption of its cryoablation technology.

$ICCMMedAI 8/10

A breast cancer study treats its first patient by freezing a tumor

IceCure Medical (ICCM) treated the first patient in its ChoICE Study at West Cancer Center, using its ProSense® cryoablation system for breast cancer. The study aims to enroll 400 patients across 30 U.S. sites, generating real-world data. ProSense® is FDA-cleared for specific breast cancer treatments. IceCure develops cryoablation therapy systems for tumor destruction.

$ICCMHighAI 8/10

IceCure Medical Wins Regulatory Approval To Market ProSense In China

IceCure Medical (ICCM) received regulatory approval from China's NMPA for its ProSense cryoablation system, expanding its global market. The device, already cleared in the U.S. and Europe, is used to treat tumors in breast, kidney, bone, and lung. The approval was supported by clinical data, and the company plans to accelerate commercialization in China. ICCM's stock is up 1.42% to $2.14.

$ICCMMed

West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation

IceCure Medical (ICCM) received IRB approval from West Cancer Center for its ChoICE study on ProSense® cryoablation for low-risk breast cancer. The study, expected to enroll patients soon, aims to gather real-world data on the treatment. ProSense® is FDA-approved for women 70+ with low-risk tumors. The study will involve 30 sites and 400 patients, expanding access to cryoablation.

$ICCMMed

IceCure Medical (ICCM) Q2 2026 Earnings Call Transcript

IceCure Medical (ICCM) reported $1.8M in H1 2026 revenue, up 45% YoY. U.S. revenue grew 64% post-FDA clearance. Gross profit rose 57% to $548K, but net loss widened to $8.8M. Cash increased to $12M after $8.5M Q2 financing. Management highlighted growth in system and disposable probe sales, U.S. expansion, and the CHOICE study.